Tests mindfulness with thinking and movement training for Parkinson's and mild memory problems
Tests mindfulness with dual-task training in people with Parkinson's and mild memory problems.
Plain-language title generated from the registry record
Registry title: Mindfulness-Enhanced Dual-Task Training in PD-MCI
Key facts
- Where
- Nanjing, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 55 and 75 years old?
Source: NCT06930742, who can take part
Where in China
- Nanjing Mingzhou Rehabilitation HospitalNanjing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Nanjing Mingzhou Rehabilitation Hospital
- Trial code
- NCT06930742
- Record updated
- 16 April 2025
- Original description
The goal of this clinical trial is to learn if Mindfulness-Enhanced Dual-Task Training work to treat PD-MCI in adults. The main questions it aims to answer are:Read full original descriptionShow less
Mindfulness-Enhanced Cognitive-Motor Dual-Task Training Using Balance and Isokinetic Systems for Parkinson's Disease With Mild Cognitive Impairment: A Randomized Controlled Trial
The goal of this clinical trial is to learn if Mindfulness-Enhanced Dual-Task Training work to treat PD-MCI in adults. The main questions it aims to answer are:
Does Mindfulness-Enhanced Dual-Task Training improve the cognitive or motor function of participants? Can the combination of Dual-Task Training and Mindfulness achieve better effects?
Researchers will compare 3 groups (Dual-Task Training + Mindfulness, Dual-Task Training, and conventional motor task training) to see if Dual-Task Training and Mindfulness works to treat PD-MCI.
Participants will:
Receive treatment for 4 weeks Receive scale and instrument testing before and after treatment
Inclusion: Age: Between 55 and 75 years; Disease Diagnosis: Clinically diagnosed with Idiopathic Parkinson's Disease (PD) according to the UK Parkinson's Disease Society Brain Bank Criteria; Disease Stage: Hoehn \& Yahr (H\&Y) stages 1 to 2.5; Cognitive Function: Montreal Cognitive Assessment (MoCA) score between 23 and 26, indicating mild cognitive impairment (MCI); Medication Stability: Stable doses of antiparkinsonian medications for at least 4 weeks prior to screening; Subjective Cognitive Complaints: Self-reported or informant-reported cognitive decline persisting for at least 6 months; Ambulatory Ability: Able to walk independently, with or without assistive devices; Sensory Abilities: Adequate vision and hearing to comply with study procedures; Informed Consent: Willingness to provide written informed consent and comply with study requirements.
Exclusion: Other Neurological Disorders: Presence of other neurological conditions that could affect cognitive function, such as Alzheimer's disease, stroke, or brain tumors; Psychiatric Conditions: Severe psychiatric disorders, including major depressive disorder or schizophrenia; Substance Abuse: Recent history of drug or alcohol abuse; Serious Medical Conditions: Uncontrolled hypertension, diabetes, heart disease, or other conditions that could interfere with study participation or outcomes; Severe Cognitive Impairment: Diagnosis of Parkinson's Disease Dementia (PDD); Other Factors Affecting Cognition: Recent head trauma, uncontrolled thyroid dysfunction, vitamin B12 deficiency, or other conditions known to affect cognitive function; Deep Brain Stimulation (DBS): History of DBS treatment. Participation in Other Clinical Trials: Participation in another clinical trial that could interfere with this study within the last 3 months.